Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Hematologic malignancy
Mesechymal stromal cell
acute graft versus host disease (aGVHD)
allogeneic transplant of haematopoietic stem cells
chronic graft versus host disease (GVHD)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
06
2022
accepted:
11
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
Despite the curative potential of hematopoietic cell transplantation (HCT) for hematologic malignancies, graft-versus-host disease (GVHD) remains a substantial cause of morbidity and mortality, particularly if treatment is refractory. Treatment with additional immunosuppression including steroids often leads to opportunistic infections and organ dysfunction. Novel therapies are greatly needed, specifically ones that lead to responses in treatment-refractory patients and are better tolerated. Mesenchymal stromal cells (MSCs) are non-hematopoietic tolerogenic cells present in normal bone marrow (BM), which can be expanded
Identifiants
pubmed: 36189324
doi: 10.3389/fimmu.2022.959658
pmc: PMC9515357
doi:
Substances chimiques
Steroids
0
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
959658Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000455
Pays : United States
Informations de copyright
Copyright © 2022 Stenger, Giver, Langston, Kota, Das, Chinnadurai, Galipeau, Waller and Qayed.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Stem Cell Rep. 2022;8(2):72-92
pubmed: 35502223
Stem Cells. 2016 Sep;34(9):2429-42
pubmed: 27299362
N Engl J Med. 2020 May 7;382(19):1800-1810
pubmed: 32320566
J Immunol. 2014 Feb 15;192(4):1491-501
pubmed: 24403533
Biol Blood Marrow Transplant. 2020 May;26(5):835-844
pubmed: 31505228
Cell Rep. 2018 Feb 27;22(9):2504-2517
pubmed: 29490284
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Aliment Pharmacol Ther. 2016 Sep;44(5):471-81
pubmed: 27385373
Bone Marrow Transplant. 2021 Oct;56(10):2355-2366
pubmed: 33976381
Biol Blood Marrow Transplant. 2020 May;26(5):e89-e91
pubmed: 32156632
Biol Blood Marrow Transplant. 2012 Apr;18(4):557-64
pubmed: 21820393
Blood. 2005 Dec 15;106(13):4057-65
pubmed: 16118325
Oncologist. 2022 Aug 5;27(8):685-693
pubmed: 35443042
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Front Immunol. 2021 Oct 26;12:761616
pubmed: 34764962
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Blood Adv. 2021 Mar 9;5(5):1352-1359
pubmed: 33656537
Biol Blood Marrow Transplant. 2020 May;26(5):855-864
pubmed: 32044400
Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182
pubmed: 32438042
Cytotherapy. 2012 Feb;14(2):147-52
pubmed: 22029655
Stem Cells Transl Med. 2017 Oct;6(10):1868-1879
pubmed: 28887912
Blood. 2003 May 1;101(9):3722-9
pubmed: 12506037
Biol Blood Marrow Transplant. 2015 May;21(5):934-40
pubmed: 25659882
Blood Adv. 2020 Apr 14;4(7):1284-1295
pubmed: 32236525
PLoS One. 2012;7(10):e47559
pubmed: 23133515
Inflamm Bowel Dis. 2015 May;21(5):963-72
pubmed: 25738379